Salbutamol in the Management of Asthma: A Review

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2022

Autores

Marques, L (Autor) Outra; Nuno Vale (Autor) FMUP

Revista

Título: International Journal Of Molecular Sciences

Vol. 23

ISSN: 1661-6596

Editora: MDPI

Indexação

ISI Web of Knowledge - 0 Citações

Scopus

Outras Informações

ID Authenticus: P-00X-FTM

DOI: 10.3390/ijms232214207

Abstract (EN): Asthma is a common inflammatory disease of the lungs. The prevalence of asthma is increasing worldwide, and the tendency indicates that the number of asthma sufferers will soar in the coming years for several reasons, in particular, the lifestyles we have adopted that expose us to risk factors. Salbutamol is the first selective short-acting beta(2)-agonist (SABA) used as an alternative reliever in the treatment of asthma. Its therapeutic effect is based on its potent smooth muscle relaxant properties, which allow the inhibition of bronchial smooth muscle contraction and subsequent bronchodilation. Salbutamol can be administered orally, intravenously (IV), intramuscularly (IM), subcutaneously, or by inhalation. For this reason, the pharmacokinetic (PK) parameters-absorption, distribution, metabolism, and elimination-are highly diverse and, consequently, the efficacy and adverse effects also differ between each formulation. Here, we review the pharmacological profile of different salbutamol formulations, focusing on their efficacy and adverse effects for its original application, asthma.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 19